Back to top
more

Biogen (BIIB)

(Real Time Quote from BATS)

$183.18 USD

183.18
350,129

-2.50 (-1.35%)

Updated Oct 7, 2024 02:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biogen (BIIB) Surpasses Q4 Earnings and Sales Estimates

by Zacks Equity Research

Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The company expects decline in sales and earnings in 2020.

Biogen (BIIB) Q4 Earnings & Sales Beat Estimates

by Zacks Equity Research

Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter.

Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More

by Zacks Equity Research

Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.

Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?

by Zacks Equity Research

Biogen's (BIIB) fourth-quarter MS franchise sales are expected to have been flat. Spinraza U.S. sales are expected to have been supported by continued patient growth.

Roche's Risdiplam Meets Primary Endpoint in Infants Study

by Zacks Equity Research

Roche's (RHHBY) risdiplam meets primary endpoint in FIREFISH study in infants with type 1 spinal muscular atrophy.

Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe

by Zacks Equity Research

Novartis' (NVS) MS drug, Mayzent, obtains approval in Europe for the treatment of adult patients with secondary progressive multiple sclerosis.

Biogen Acquires Early-Stage CNS Drug From Pfizer for $75M

by Zacks Equity Research

Biogen (BIIB) signs deals with Pfizer to acquire rights to a CNS candidate and develop it as potential therapy to treat certain symptoms/disorders related to Alzheimer's disease and Parkinson's disease.

The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals

AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU

by Zacks Equity Research

AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives approval in Europe for treating rheumatoid arthritis under the trade name of Rinvoq.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More

by Zacks Equity Research

The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.

Biogen's Gosuranemab Fails in Phase II Brain Disorder Study

by Zacks Equity Research

Biogen's (BIIB) gosuranemab fails to meet primary endpoint in a phase II study evaluating gosuranemab (BIIB092) in patients with progressive supranuclear palsy, a degenerative brain disorder.

J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH

by Zacks Equity Research

J&J's (JNJ) initial data on CAR-T therapy candidate JNJ-68284528 from an early-stage study shows promising response rate.

Biogen Up on New Data on Alzheimer's Candidate Aducanumab

by Zacks Equity Research

Biogen (BIIB) divulges new positive data on Alzheimer's candidate, aducanumab at CTAD. Stock rises.

Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up

by Zacks Equity Research

Aurinia's (AUPH) lupus candidate, voclosporin, met primary endpoint of renal response rate in a late-stage study. An NDA is expected in the first half of 2020.

Biogen's Lupus Candidate Meets Endpoint in Phase II Study

by Zacks Equity Research

Biogen (BIIB) posts favorable top-line results from a phase II study evaluating BIIB059 for treating cutaneous and systemic lupus erythematosus. The study tastes success by achieving its main goal.

Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More

by Zacks Equity Research

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

Biogen's Shares Down on Rating Downgrade by Baird Analyst

by Zacks Equity Research

Biogen's (BIIB) shares decline following a rating downgrade by an analyst at Robert W. Baird on concerns related to approval of Alzheimer's disease candidate, aducanumab.

Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More

by Zacks Equity Research

Key highlights of the past week include regulatory and pipeline updates.

ChemoCentryx Up on Encouraging Rare Disease Candidate Data

by Zacks Equity Research

ChemoCentryx (CCXI) announces positive data pivotal study evaluating its lead candidate, avacopan, in patients with ANCA vasculitis, a rare disease affecting small blood vessels.

The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Kinjel Shah headshot

4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal

by Kinjel Shah

Here are four stocks that boast promising prospects and are most likely to be takeout targets.

Roche's NDA for SMA Drug Risdiplam Gets Priority Review

by Zacks Equity Research

The FDA accepts Roche's (RHHBY) NDA for risdiplam under a priority review to treat spinal muscular atrophy. A verdict is pending on May 24, 2020.

Biogen Ends Enrollment in Eye Disorder Study on Gene Therapy

by Zacks Equity Research

Biogen (BIIB) completes enrollment in the global phase III STAR clinical study evaluating the gene therapy timrepigene emparvovec for the treatment of a rare, inherited retinal disorder.